Jul 16, 2026
Eli Lilly (LLY) Acquires Psychedelic Drug Developer AtaiBeckley in $2.8B Deal
Eli Lilly (LLY) stock announces $2.8B acquisition of AtaiBeckley to gain access to experimental DMT nasal spray for treatment-resistant depression.
The post Eli Lilly (LLY) Acquires Psychedelic Drug Developer AtaiBeckley in $2.8B Deal appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
SEALSQ Corp (LAES) Stock Climbs on $200M Quantum Technology Initiative Progress
- 3 hours ago
SpaceX (SPCX) Stock: Expands AI Cloud Business With $20.8 Billion in New Contrac...
- 3 hours ago
SanDisk (SNDK) Stock Rebounds in Premarket Despite Post-Earnings Volatility
- 3 hours ago
SK Hynix (000660) Stock: $3B China Facility Under Strategic Review Amid Export C...
- 3 hours ago
First Solar (FSLR) Stock Soars 8% on Trump’s Chinese Polysilicon Tariff Announce...